Psych Elevate

June 3 - 6
Las Vegas, NV

Tardive Dyskinesia

 

Clinical Guidance for the Use of VMAT2 Inhibitors to Treat Tardive Dyskinesia: Insights From a Multidisciplinary Panel

Authors:
Chelsie Monroe, Cherian Karunaouzha, Jonathan Mever, Gustavo Alva, Kavla Johnson, Robert Morton, Susan Scanland

Download the poster

Tardive Dyskinesia Educational Efforts With United States–Based Patient Advocacy Groups: An Interim Analysis of Digital Engagement With Caregivers

Authors:
Mark Henegar, Michelle Roberts, Diana Klakotskaia, Theresa Nguyen, Leah Wentworth, Weixiu Luo, Brett Talbot, Stacy Finkbeiner

Download the poster

Deutetrabenazine Long-Term Treatment Response in Adults With Tardive Dyskinesia in the RIM-TD Open-Label Extension Study: Analysis of Treatment Response Patterns

Authors:
Stacy Finkbeiner, Pooja Gandhi, Steve Barash, Martijn Konings

Download the poster

Characterization of Patients With Mild Tardive Dyskinesia Taking Deutetrabenazine in the IMPACT-TD Registry

Authors:
Richard Jackson, MD, Diana Klakotskaia, PhD, Martijn Konings, MSc, Daisy Yu, PhD, Stacy Finkbeiner, PhD

Download the poster
 

Long Acting Injectable

 

Inpatient Length of Stay and Healthcare Professional Preferences for Initiating TV-46000, a Long-Acting Subcutaneous Antipsychotic, or Intramuscular Paliperidone Palmitate in Patients Hospitalized With Schizophrenia

Authors:
Ayush Patel, Arti Phatak, Rolf T. Hansen Julian Casciano, Zenobia Dotiwala, Kelli R. Franzenburg, Mark Suett, Ayelet Yaari

Download the poster

Impact of Adherence on Post-Discharge Outcomes With Long-Acting Injectable Olanzapine Pamoate or Paliperidone Palmitate After Schizophrenia Hospitalization

Authors:
John M. Kane, Sangtaeck Lim, Rolf Hansen, Mike Philbin, Kelli R. Franzenburg, Ying Zhang, Arti Phatak, Mark Suett, Ana Filipa Alexandre, Li Wang Sameer, Kotak, Jose M. Rubio

Download the poster

Characterization of Injection Site Reactions and Local Tolerability with Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) in Adults with Schizophrenia: Results from the Phase 3 SOLARIS Trial

Authors:
Christoph U. Correll, Tamar Bar-Nur, Rotem Gidron-Budovsky, Nir Sharon, Kelli R. Franzenburg, Mark Suett, Ortal Pelleg, Helena Knebel, Anna Elgart

Download the poster

Healthcare Professional Perspectives on Real-world Use of TV-46000, a Long-Acting Subcutaneous Formulation of Risperidone, for Bipolar I Disorder

Authors:
Arti Phatak, Rolf T. Hansen, Ayush Patel, Mark Suett, Zenobia Dotiwala, Essy Mozaffari, Julian Casciano, Jennifer Parish, Ying Zhang, Ayelet Yaari

Download the poster